Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 229

1.

Pre-operative dopamine agonist therapy improves post-operative tumor control following prolactinoma resection.

Sughrue ME, Chang EF, Tyrell JB, Kunwar S, Wilson CB, Blevins LS Jr.

Pituitary. 2009;12(3):158-64. doi: 10.1007/s11102-008-0135-1.

PMID:
18651225
2.

The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.

Soule SG, Farhi J, Conway GS, Jacobs HS, Powell M.

Clin Endocrinol (Oxf). 1996 Jun;44(6):711-6.

PMID:
8759184
3.

Surgery combined with dopamine agonists versus dopamine agonists alone in long-term treatment of macroprolactinoma: a retrospective study.

Höfle G, Gasser R, Mohsenipour I, Finkenstedt G.

Exp Clin Endocrinol Diabetes. 1998;106(3):211-6.

PMID:
9710362
4.
5.

Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.

Wu ZB, Su ZP, Wu JS, Zheng WM, Zhuge QC, Zhong M.

Pituitary. 2008;11(1):63-70.

PMID:
17917811
6.

Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.

Kars M, Pereira AM, Smit JW, Romijn JA.

Eur J Intern Med. 2009 Jul;20(4):387-93. doi: 10.1016/j.ejim.2008.11.012. Epub 2008 Dec 30.

PMID:
19524180
7.

Hyperprolactinemia: pathophysiology and management.

Verhelst J, Abs R.

Treat Endocrinol. 2003;2(1):23-32. Review.

PMID:
15871552
8.

Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.

Glaser B, Nesher Y, Barziliai S.

J Reprod Med. 1994 Jun;39(6):449-54.

PMID:
7932398
9.

Surgery, dopamine agonist therapy of combined treatment--results in prolactinoma patients after a 12 month follow-up.

Hildebrandt G, Bauer T, Stracke H, Fassbender WJ, Mueller HW, Agnoli AL, Federlin K, Roosen K.

Zentralbl Neurochir. 1992;53(3):123-34.

PMID:
1414079
10.

Gamma knife radiosurgery for medically and surgically refractory prolactinomas.

Pouratian N, Sheehan J, Jagannathan J, Laws ER Jr, Steiner L, Vance ML.

Neurosurgery. 2006 Aug;59(2):255-66; discussion 255-66.

PMID:
16883166
12.

Combined treatment of invasive giant prolactinomas.

Yu C, Wu Z, Gong J.

Pituitary. 2005;8(1):61-5.

PMID:
16411070
13.

[Treatment of prolactinoma with a new dopamine agonist].

Svoboda T, Luger A, Knosp E, Geyer G.

Dtsch Med Wochenschr. 1991 Aug 16;116(33):1224-7. German.

PMID:
1678695
14.

10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.

Andereggen L, Frey J, Andres RH, El-Koussy M, Beck J, Seiler RW, Christ E.

Endocrine. 2017 Jan;55(1):223-230. doi: 10.1007/s12020-016-1115-2. Epub 2016 Sep 29.

PMID:
27688009
15.

[Hyperprolactinemia and prolactinomas. Results of surgical and drug therapy].

Brabant G, Brennecke I, Herrmann H, Friedrich H, Wagner TO, von zur Mühlen A, Hesch RD.

Dtsch Med Wochenschr. 1985 Oct 11;110(41):1564-7. German.

PMID:
4042883
16.

Clinical management and outcome of 36 invasive prolactinomas treated with dopamine agonist.

Yang MS, Hong JW, Lee SK, Lee EJ, Kim SH.

J Neurooncol. 2011 Aug;104(1):195-204. doi: 10.1007/s11060-010-0459-3. Epub 2010 Nov 24.

PMID:
21107645
17.

[Results of treatment for male prolactinomas].

Iwai Y, Yamanaka K, Ishiguro T, Morikawa T, Matsuzaka Y, Komiyama M, Yasui T.

No Shinkei Geka. 2002 Dec;30(12):1285-92. Japanese.

PMID:
12491580
18.

Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy.

Berinder K, Nyström T, Höybye C, Hall K, Hulting AL.

Pituitary. 2011 Sep;14(3):199-207. doi: 10.1007/s11102-010-0277-9.

PMID:
21128120
19.
20.

Prolactinomas and resistance to dopamine agonists.

Brue T, Pellegrini I, Priou A, Morange I, Jaquet P.

Horm Res. 1992;38(1-2):84-9.

PMID:
1306523

Supplemental Content

Support Center